Journal
Hims vs Ro in 2026: Two Post-Compounded Platforms, Two Different Bets
Released: Last reviewed:
The short answer
The two most famous names in telehealth weight loss now sell the same FDA-approved products on opposite theses. Hims & Hers (post its March 9, 2026 Novo settlement): a brand storefront on a $149 membership — Wegovy, oral Wegovy, and Zepbound at all-ins of roughly $448, $398, and $548, betting that platform convenience justifies a $99–$249 monthly premium over the manufacturers' own counters. Ro: an insurance-first concierge — benefits checks, prior authorizations, appeals — that wins our computed best-with-insurance category by converting covered-in-theory into $25-copays-in-practice, with a cash fallback ($448–$598 all-in) that's ordinary reseller pricing. The comparison therefore isn't head-to-head; it's a routing switch: insured or plausibly insurable → Ro's concierge earns its place; confirmed cash-pay → neither, because LillyDirect and NovoCare sell the same vials, pens, and tablets for less with no membership.
The theses, stress-tested
Hims' bet survives one test: a subscriber already paying the $149 for other care (its original categories), for whom the GLP-1 marginal math is just the medication line — still above the direct channels' prices, but inside one familiar app. For a weight-only customer the arithmetic never closes: $99–$249 monthly buys convenience the manufacturers' own checkouts now match, and our full review runs every line. Ro's bet survives a bigger one: the three human steps where coverage actually dies (the benefits call, the PA package, the appeal) are genuinely worth paying someone to execute — a $500-cash-problem-to-$25-copay conversion no cash program can match — with the caveats our review attaches: confirm coverage runs first, the cash tier is a fallback not a funnel, and the service's cost against a landed copay is stated upfront. Shared honest footnote: both platforms' pre-2026 fame was built on compounded pricing neither now offers — the cheap tier they vacated lives on at the independent programs this site ranks, which is where confirmed cash-pay buyers were headed anyway.
Questions people ask
Is Hims or Ro better for GLP-1s in 2026?
Route by coverage: insured or plausibly insurable → Ro (its concierge converts coverage into $25 copays — our best-with-insurance category winner); confirmed cash-pay → neither; LillyDirect ($299–$449 for Zepbound with the 45-day refill rule) and NovoCare ($149–$349, or $399 for Wegovy HD 7.2 mg) sell the identical products for less with no membership.
Do Hims or Ro still sell compounded semaglutide?
Not to new patients: Hims exited via its March 2026 Novo settlement; Ro completed its pivot to brand-plus-concierge. Both are brand-only storefronts now — the compounded tier they made famous lives on at independent programs ($99–$179) with the standard verification homework.
What do Hims and Ro actually cost per month?
All-in at maintenance: Hims ~$448 (Wegovy), $398 (oral), $548 (Zepbound) including its $149 membership; Ro ~$448–$598 cash. Both sit above the manufacturers' direct prices — Ro's value is the insurance work, not the cash tier.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.